

Merative Micromedex

Shou Ray Information Service

2023

Trainer | Nicole

大綱

Micromedex 內容簡介

Micromedex 使用介面

Micromedex 各類檢索與工具

Micromedex Assistant – 有問題，MA來幫你！

Micromedex 內容簡介

Micromedex 收錄內容範圍



藥物資訊



治療方式



藥物毒性



替代療法



病患衛教

Micromedex® Solutions Healthcare Series

內容特性



權威性

藥物、毒理、疾病與急診醫學內容受美國國務院採納為官方醫學百科




高品質

嚴謹的編輯過程



專業可靠

為學校、醫院及藥廠等提供實證內容服務超過40年



內容一致

呈現格式與內容標準皆維持一致



全文閱讀


內容皆具完整參考文獻、經由同儕評審，並由臨床醫師撰寫

資料來源與編輯方法



檢閱全球的醫療文獻

>15,000篇醫學文獻/週
監控約 8,500 本期刊
定期進行高階及深度檢閱



內部編輯團隊

擁有研究方法專業知識並
受過臨床訓練的編輯專員

資料來源

Drug Information	Disease Information
DRUGDEX[®] System DRUG-REAX[®] System MARTINDALE	DISEASEDEX[™] General Medicine DISEASEDEX[™] Emergency Med. Lab adviser[™]
Index Nominum Physicians' Desk Reference[®](PDR[®]) P & T QUIK[®] Reports	Patient Education
IV INDEX[®] System MSDS from USP IDENTIDEX[®] System	AltCareDex[®] Alternative Medicine Education CareNotes[™] System
Red Book[®] Online KINETIDEX[®] System	Toxicology Information
Alternative Medicine	Free Resources
AltMedDex[®] System AltMedDex[®] Protocols	Calculators Micromedex Apps

Micromedex 使用

資料庫登入與使用



IP認證機制

- 在IP範圍內，從單位圖書館網頁連結
- 校 / 院外連線：設定Proxy或VPN
- 有同時上線人數限制
- **養成好習慣，用完要登出**
- **完整全文內容**



行動載具APP 訂戶專屬

- 每次登入會自動更新資料
- **可離線使用**，不受網路死角影響
- **僅有簡要解答內容**

*更新資料時需有網路

APP下載

Micromedex
Drug Reference



Micromedex
Drug Interactions



Micromedex
IV Compatibility



可離線使用，不受制於使用人數

APP使用方式



Merative mobile **Micromedex**[®]
Put the power of Micromedex on your mobile device

↓ Micromedex Native Mobile Apps (Offline access, included with content subscription)

Micromedex Apps on Apple[®] and Android[®]


Micromedex[®] Drug Reference




- The **Micromedex Drug Reference** app for Apple and Android devices is included with Merative Micromedex Drug content subscription.
- You can access these apps via the App Store and Google Play[®].
- You can activate the app by following the simple instructions below.

Simple instructions for installation:


- Step 1:** Visit the App Store from your device and search Micromedex Drug Reference.
- Step 2:** From the App, select download / install the application. You may be prompted to enter your Apple or Google ID.
- Step 3:** The app will download to your app library, or directly to your device.
- Step 4:** Open the app. Enter the password [redacted] to begin using **Micromedex Drug Reference**. *The password is case-sensitive. Please enter it exactly as it appears here.*




手機APP使用畫面




手機APP使用畫面



手機APP使用畫面



手機APP使用畫面



APP小提醒

- 只有**簡要解答 (Summary)**
 - 深入解答仍需回到Micromedex網頁查詢
- 密碼到期
 - 新密碼的取得須在**IP範圍內登入Micromedex** 資料庫，進入 **下載中心** 頁面或  即可找到。



資料庫介面

3 支援總覽

2 工具列

1 檢索區

Merative Micromedex®

[我的訂閱](#) | [關道](#) | [Training Center](#) | [說明](#) | [下載中心](#) | [登出](#)

主頁

藥物
相互作用

IV 相容性

藥物
鑑定

藥物
比較

CareNotes

NeoFax® /
Pediatrics

Tox 和藥物
產品查找

RED BOOK

計算器

搜尋藥物、疾病、毒理學及其他資訊

全部

藥物

疾病

毒理學

Keyword search



Ask Watson

Search Micromedex drug information

Type a quick question...



[Learn more](#)



最新消息

- Evusheld(TM): Emergency Use...
- Orserdu(TM) for ESR1-Mutated Breast...
- Jaypirca(TM) for MCL
- Keytruda(R): 5th NSCLC Indication
- Content Update Highlights

4

Read Top News



支援和訓練

- Training Center
- User Guide
- Micromedex Compendia Resources
- Citing Micromedex

5

Support Request



資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

6



Download Mobile Apps

我的訂閱

我的訂閱 | 簡道 | Training Center | 說明 | 下載中心 | 登出

Merative **Micromedex**[®]

- 主頁
- 藥物相互作用
- IV 相容性
- 藥物鑒定
- 藥物比較
- CareNotes
- NeoFax[®] / Pediatrics
- Tox 和藥物產品查找
- RED BOOK
- 計算器

搜尋藥物、疾病、毒理學及其他資訊

全部 藥物

Keyword search

已經訂購

尚未訂購

Ask Watson

edex drug information

question...

Learn more ?

Your Subscribed Products	Non-subscribed Products
<p>MICROMEDEX</p> <ul style="list-style-type: none"> ▶ AAPCC Codes in POISINDEX ▶ Alternative Medicine ▶ Detailed Drug Information for the Consumer ▶ DISEASEDEX™ Emergency Medicine ▶ DISEASEDEX™ General Medicine ▶ DRUGDEX System ▶ Imprint Codes in Identidex ▶ Index Nominum ▶ Interaction Checking ▶ Italian Drug Database ▶ IV Compatibility ▶ Lab Advisor ▶ MARTINDALE ▶ Micromedex with Watson Integrated Delivery ▶ NeoFax[®] ▶ P&T QUIK Reports ▶ Pediatrics ▶ POISINDEX Managements 	<p>MICROMEDEX</p> <ul style="list-style-type: none"> ▶ API CareNotes and DrugNotes ▶ API In-Depth Drug ▶ API Summary Drug ▶ United Kingdom Drug Information ▶ Watson Assistant for Mobile Browsers

最新消息

- Evusheld(TM): Emergency Use...
- Orserdu(TM) for ESR1-Mutated Bre...
- Jaypirca(TM) for MCL
- Keytruda(R): 5th NSCLC Indication
- Content Update Highlights

Read Top News

資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

Download Mobile Apps

Training Center

最新消息

- Vioice(R) for PROS
- Yescarta(R): 2nd-Line LBCL Treatment
- Content Update Highlights
- Pregnancy Info in Drug

支援和訓練

- Training Center
- User Guide
- Micromedex Compendia Resources

資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List

Read Top News

Micromedex Training Center | Merative - Google Chrome
merative.com/micromedex-training-center

merATIVE Solutions ▾ Who we serve ▾ Our company ▾ Resources ▾ Contact us

Micromedex Training Center

Nurses

Be prepared for any patient you encounter with evidence-based content, drug interaction checker, calculators and other tools.

Pharmacists

Get fast access to current drug information to resolve complex drug therapy issues and support patient safety.

Physicians

Stay current on the latest drug and disease evidence with daily, reliable clinical updates.

Feedback

最新消息

最新消息

- Vijoice(R) for PROS
- Yescarta(R): 2nd-Line LBCL Treatment
- Content Update Highlights
- Pregnancy Info in Drug Interactions

支援和訓練

- Training Center
- User Guide

資源

- 黑框警告
- Comparative Tables

Latest News

關閉 X

Read Top News

▶ Vjoice(R) for PROS

On April 6, 2022, the US FDA approved Vjoice(R) (alpelisib) oral tablets indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. Vjoice treats PROS, which is a spectrum of rare conditions characterized by overgrowths and blood vessel anomalies, by inhibiting the PIK3 pathway and is the first FDA-approved treatment for PROS. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Prescribing information can be found at https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215039s000lbledt.pdf.

Last modified: 04/12/2022 11:37:09

Full Article 

▶ Yescarta(R): 2nd-Line LBCL Treatment

▶ Content Update Highlights

▶ Pregnancy Info in Drug Interactions

Apps

引用 Micromedex

最新消息

- Vioice(R) for PROS
- Yescarta(R): 2nd-Line LBCL Treatment
- Content Update Highlights
- Pregnancy Info in Drug Interactions

支援和訓練

- Training Center
- User Guide
- Micromedex Compendia Resources
- **Citing Micromedex**

資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

Read Top News

Merative: Warranty & Disclaimer - Google Chrome
micromedexsolutions.com/micromedex2/librarian/CS/EC47RD/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/86BE30/ND_PG/evidencexpert/ND_B/evid...

HOW TO REFERENCE THE Merative SYSTEMS

↑ Top of page

PLEASE NOTE: When referencing a Micromedex product or database, you *must* include: (electronic version), Merative information, URL address (<https://www.micromedexsolutions.com/>) and the date accessed. Subscribers to the Licensed Solutions often ask how to reference the databases when publishing articles. The following formats should be used:

The entire Micromedex System:

↑ Top of page

Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: month/day/year).

An entire System or Database:

↑ Top of page

Merative™ Micromedex® Alternative Medicine:
Merative™ Micromedex® Alternative Medicine (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: month/day/year).

CareNotes®:
CareNotes® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: month/day/year).

Merative™ Micromedex® Disease Emergency Medicine:
Merative™ Micromedex® Disease - Emergency Medicine (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: month/day/year).

Merative™ Micromedex® Disease General Medicine:
Merative™ Micromedex® Disease - General Medicine (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: month/day/year).

Dosing & Therapeutic Tools Database:
Dosing & Therapeutic Tools Database (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: month/day/year).

Merative™ Micromedex® DRUGDEX®:
Merative™ Micromedex® DRUGDEX® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: month/day/year).

Merative™ Micromedex® Drug Interaction Checking:
Merative™ Micromedex® Drug Interaction Checking (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: month/day/year).

MARTINDALE:
Sweetman S (Ed). Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Electronic version, Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: month/day/year).

Merative™ Micromedex® POISINDEX®:
POISINDEX® System (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: month/day/year).

Merative™ Micromedex® Reproductive Effects:

Mobile Apps

常用資源 RESOURCES

最新消息

- Vioice(R) for PROS
- Yescarta(R): 2nd-Line LBCL Treatment
- Content Update Highlights
- Pregnancy Info in Drug Interactions

Read Top News



支援和訓練

- Training Center
- User Guide
- Micromedex Compendia Resources
- Citing Micromedex

Support Request



資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



Download Mobile Apps

以藥物首字母序條列有黑框警告的藥物
 研究表明該藥物具有嚴重、甚至危及生命的不良反應風險，是美國食品藥品監督管理局（FDA）對上市藥物採取的最嚴厲警告形式

黑框警告

跳轉到： A B C D E F G H I J K L M N **O** P Q R S T U V W X Y Z 0-9

顯示 30 of 999 條結果，帶有黑框警告

Obeticholic Acid

Obiltoxaximab

Obinutuzumab

Ofatumumab

Ofloxacin

Olanzapine

Olanzapine Pamoate

Ofloxacin

Drug Classes: [Antibacterial](#) | [Antibiotic](#) | [All](#)

Routes: [Ophthalmic](#) | [Oral](#) | [Otic](#)

Regulatory Authority

FDA

簡要解答
深入解答
全部結果

Dosing/Administration

- [Adult Dosing](#)
- [Pediatric Dosing](#)
- [FDA Uses](#)
- [Non-FDA Uses](#)
- [Dose Adjustments](#)
- [Administration](#)
- [Comparative Efficacy](#)
- [Place In Therapy](#)

Medication Safety

- [Contraindications](#)
- [Precautions](#)
- [Adverse Effects](#)
- [Black Box Warning](#)

Medication Safety

Black Box Warning [列印](#)

請參閱 '深入解答' 瞭解詳細結果。

Oral (Tablet)

- Fluoroquinolones, including ofloxacin, are associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue ofloxacin and avoid use of fluoroquinolones in patients with these serious adverse reactions. Reserve use of ofloxacin for patients with no alternative treatment options for acute exacerbation of chronic bronchitis or uncomplicated cystitis. Fluoroquinolones, including ofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid in patients with known history of myasthenia gravis [2].

相關結果

- [替代藥物](#)
- [毒理學](#)
- [疾病](#)

- [Drug Consults](#)
- [Index Nominum](#)
- [Martindale](#)
- [PDR®](#)
- [Product Lookup - Martindale](#)
- [Product Lookup - RED Book](#)
- [Product Lookup - Tox & Drug](#)
- [消費者藥物資訊](#)

Ask Watson

merATIVE

30

Dosage

Class

▶ BENZODIAZEPINES (SELECTED)

▶ CORTICOSTEROIDS (SELECTED) PROPERTIES AND POTENCIES

▶ NSAID (NONSTEROIDAL ANTIINFLAMMATORY AGENTS (SELECTED))

Oral NSAIDs

Generic Name	Brand Name (US)	Indications	Effective Dosage Range
Diclofenac	Cataflam (diclofenac potassium immediate-release tablets)	Pain	50 mg 3 times daily
		Dysmenorrhea	50 mg 3 times daily
		Osteoarthritis	50 mg 2 to 3 times daily
		Rheumatoid Arthritis	50 mg 3 to 4 times daily
	Voltaren (diclofenac sodium enteric-coated tablets)	Ankylosing Spondylitis	25 mg 4 times daily, with an extra 25 mg at bedtime if needed
		Osteoarthritis, Rheumatoid Arthritis	50 mg 2 to 3 times daily, or 75 mg twice daily
	Voltaren XR (diclofenac sodium extended-release tablets)	Osteoarthritis	100 mg every day
Rheumatoid Arthritis		75 to 100 mg once or twice daily	

Dosage

Class

▶ ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS (SELECTED)

▶ ANTIDIABETIC AGENTS (SELECTED)

▶ BETA BLOCKERS

Generic Drug Name And Brand Name	Usual Dosage Range*	Maximum Daily Dose	Drug Class	Hypoglycemia Risk**	Weight Change**	GI Symptoms**
Acarbose (Precose(R))	25 to 100 mg ORALLY 3 times daily with meals	60 kg or less: 150 mg; Greater than 60 kg: 300 mg	AGI	not significant	not significant	diarrhea, flatulence
Alogliptin (Nesina(R))	25 mg ORALLY once daily	---	DPP-4 inhibitor	not significant	not significant	not significant
Alogliptin Benzoate/Metformin (Kazano)	alogliptin 12.5 mg/metformin 500 mg to alogliptin 12.5 mg/metformin 1000 mg ORALLY twice daily with meals	alogliptin 25 mg/metformin 2000 mg	DPP-4 inhibitor /Biguanide	***	***	***
Alogliptin/Pioglitazone(Oseni)	alogliptin 25 mg/pioglitazone 15 mg to alogliptin 25 mg/pioglitazone 45 mg ORALLY once daily	alogliptin 25 mg/pioglitazone 45 mg	DPP-4 inhibitor/ TZD	***	***	***

Drug Consults

跳轉到 : **A** B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

顯示 55 of 628 藥物諮詢文章

Abbreviations


Abuse-Deterrent Opioid Medications

ABVD - Used for Hodgkin's Disease

治療霍奇金氏淋巴瘤的藥物

AC - Used for Breast Cancer

ABVD - Used for Hodgkin's Disease

藥物諮詢 

AC FOLLOWED BY T WITH TRASTUZUMAB

RESPONSE

- DOXOrubicin 25 mg/m(2) IV, days 1 and 15
- Bleomycin 10 mg/m(2) IV, days 1 and 15
- VinBLAStine 6 mg/m(2) IV, days 1 and 15
- Dacarbazine 375 mg/m(2) IV, days 1 and 15 [1]
- Repeat cycle every 28 days

Reference

1. Bonadonna G & Santoro A: ABVD chemotherapy in the treatment of Hodgkin's disease. Cancer Treat Rev 1982; 9(1):21-35.
PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>
PubMed Article: <http://www.ncbi.nlm.nih.gov/...>

Last Modified: February 06, 2017

REMS (Risk Evaluation & Mitigation Strategy) 藥物風險評估暨管控計畫

跳轉到： [A](#) [B](#) [C](#) [D](#) [E](#) **[F](#)** [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#) [0-9](#)

Displaying 3 of 78 results for "REMS"

Fentanyl

類鴉片止痛劑

Elements to Assure Safe Use, Implementation System, Medication Guide

Fentanyl Citrate

Fingolimod Hydrochloride

Fentanyl

Drug Classes: [Analgesic](#) | [Central Nervous System Agent](#) | [All](#)

Routes: **Sublingual** | **Transdermal**

簡要解答

深入解答

全部結果

連結到藥品安全訊息和用藥指南

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy
- Medication Safety
- Contraindications

Medication Safety

列印

REMS

Summary

- to reduce serious adverse outcomes (eg, addiction, unintentional overdose, death) resulting from inappropriate prescribing, misuse, and abuse of extended-release or long-acting opioid analgesics while maintaining patient access to pain medications
- to mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors by: prescribing and dispensing transmucosal immediate release fentanyl medicines only to appropriate patients, which includes use only in opioid-tolerant patients; preventing inappropriate conversion between transmucosal immediate release fentanyl medicines; preventing accidental exposure to children and others for whom it was not prescribed

35



主頁	藥物相互作用	IV 相容性	藥物鑒定	藥物比較	CareNotes	NeoFax® / Pediatrics	Tox 和藥物產品查找	RED BOOK	計算器
----	--------	--------	------	------	-----------	----------------------	-------------	----------	-----

Fentanyl

Drug Classes: [Analgesic](#) | [Central Nervous System Agent](#) | [All](#)

Routes: [Sublingual](#) | [Transdermal](#)

Substance

Fentanyl

1.減少不良的後果 (成癮、無心過量、死亡)
2.減輕誤用、濫用、過量、成癮的風險

簡要解答

深入解答

全部結果

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS**
- Drug Interactions (single)
- IV Compatibility (single)

Medication Safety

REMS

Summary

- Duragesic(R) (Opioid Analgesic REMS): To make a REMS-compliant education program available to healthcare professionals (including nurses and pharmacists) regarding the treatment and monitoring of patients with pain.
- To counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products.
- To emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist,
- To consider other tools to improve patient, household, and community safety.
- lonsys(R) (lonsys REMS): To reduce serious adverse outcomes (eg, addiction, unintentional overdose, death) resulting from inappropriate prescribing, misuse, and abuse of extended-release or long-acting opioid analgesics while maintaining patient access to pain medications
- To mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors by: prescribing and dispensing transmucosal immediate release fentanyl medicines only to appropriate patients, which includes use only in opioid-tolerant patients; preventing inappropriate conversion between transmucosal immediate release fentanyl medicines; preventing accidental exposure to children and others for whom it was not prescribed
- To educate prescribers, pharmacists, and patients on the potential for misuse, abuse, addiction, and overdose of transmucosal immediate release fentanyl medicines
- To inform patients or caregivers about the serious risks associated with transmucosal immediate release and extended-release or long-acting fentanyl treatment
- Subsys(R), Fentanyl buccal (Actavis) (Transmucosal Immediate-Release Fentanyl (TIRF) Products REMS): To mitigate the risk of overdose by requiring documentation of opioid tolerance with every TIRF prescription for outpatient use and requiring inpatient pharmacies to develop policies and procedures to verify opioid tolerance in inpatients who require TIRF medicines while hospitalized as well as educating prescribers, pharmacists and patients that the safe use of TIRF medicines requires patients to be opioid-tolerant throughout treatment



相關結果

毒理學
疾病

- Drug Consults
- Index Nominum
- Martindale
- Product Lookup - Martindale
- Product Lookup - RED Book
- Product Lookup - Tox & Drug
- 消費者藥物資訊



Ask Watson

檢索與工具運用案例

常見藥品諮詢問題種類

- 劑量(肝腎功能不良、老人、兒童)之調整及投藥方式
- 藥物不良反應
- 藥品交互作用
- 藥物動力學
- 適應症
- 中毒或藥品過量的處理
- 其他，如：相容性、禁忌、費用、配製、安定性、貯存等

藥師綜合個案的問題

- 醫生考慮

一位75歲有心房顫動合併高血壓的病人，應該使用抗凝血藥物預防中風嗎？

- 病人需求

本人表示之前曾使用過Aspirin，但覺得吃了胃不舒服，所以不太喜歡...

- 家屬關心

擔心使用抗凝血藥物預防中風，是否會增加出血風險？

資料來源：新光吳火獅紀念醫院 劉人瑋藥師

利用Micromedex尋求支持的證據

Merative **Micromedex**[®]

My Subscription | Gateway | Training Center | Help
| Mobile Application Access | Logout

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax[®] / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Other Tools ▾

Search Drug, Disease, Toxicology, and more

All
Drug
Disease
Toxicology

aspirin

Aspirin

- Dosing Aspirin
- Adverse Effects Aspirin
- Indications Aspirin
- Interactions Aspirin
- Aspirin (Buffered)
- Dosing Aspirin (Buffered)
- Adverse Effects Aspirin (Buffered)

Micromedex Assistant

Search Micromedex drug information

Type a quick question... →

[Learn more](#)

Support & Training

- Center
- Compendia Resources
- Citing Micromedex

Resources

- Black Box Warnings
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

Aspirin- Uses

Aspirin

Drug Classes: [Analgesic](#) | [Antipyretic](#) | [All](#)

Routes: [Oral](#) | [Rectal](#)

Regulatory Authority



FDA



簡要解答

深入解答

全部結果

Dosing/Administration

Adult Dosing

Pediatric Dosing

FDA Uses

Non-FDA Uses

Dose Adjustments

Administration

Comparative Efficacy

Place In Therapy

Medication Safety

Contraindications

Precautions

Adverse Effects

Black Box Warning

REMS

Drug Interactions
(single)

IV Compatibility (single)

Dosing/Administration

Non-FDA Uses



列印

請參閱 '深入解答' 瞭解詳細結果。

- Adenocarcinoma of esophagus; Prophylaxis [i](#)
- Atrial fibrillation - Thromboembolic disorder; Prophylaxis [i](#)
- Cancer - Thromboembolic disorder; Prophylaxis [i](#)
- Carotid artery stenosis [i](#)
- Colorectal cancer, Nonmetastatic, post diagnosis [i](#)
- Colorectal cancer; Prophylaxis [i](#)
- Coronary stent stenosis, Subacute; Prophylaxis [i](#)
- Death, Primary prevention in women [i](#)
- Disorder of cardiovascular system, Secondary Prophylaxis [i](#)
- Flushing, Niacin Induced [i](#)
- In vitro fertilization - Pregnancy-induced hypertension; Prophylaxis [i](#)

相關結果

替代藥物

毒理學

疾病

Drug Consults

Index Nominum

Martindale

P&T QUIK 報告

PDR®

Product Lookup - Martindale

Product Lookup - RED Book

Product Lookup - Tox & Drug

消費者藥物資訊



Ask Watson

Aspirin- Comparative Efficacy

考量問題：是否有其他藥物可選擇？

ASPIRIN

Drug Classes: Analgesic | Antipyretic | All

Routes: Oral | Rectal

Regulatory Authority

The screenshot shows a search interface with tabs for 'Summary Answer', 'Deep Answer', and 'All Results'. The search query is 'Atrial fibrillation - Thromboembolic disorder'. Below the search bar, there are filters for 'Adult Dosing' (USA) and 'Normal Dosage'. A list of search results is visible, with the first result being 'ASPIRIN'. The 'ASPIRIN' entry includes drug classes, routes, and a detailed description of its use in atrial fibrillation. A 'Beers Criteria' note is also present, indicating that aspirin should be used with caution in certain patients. The 'Deep Answer' tab is selected, showing a detailed summary of the drug's efficacy in preventing stroke in atrial fibrillation patients.

b) 在一項 1007 名門診患者的對照研究中，華法林在預防慢性非風濕性心房顫動的血栓栓塞併發症和血管死亡方面優於阿司匹林。...只要不存在禁忌症，慢性心房顫動患者應考慮使用華法林進行抗凝治療。

c) BAATAF (波士頓地區房顫抗凝試驗) 研究：華法林在預防非風濕性房顫患者中風方面優於阿司匹林。在這項研究中，華法林使用者的年中風發生率為 0.45%，而阿司匹林使用者為 3.9%，未經治療的患者為 1.8%

Ask Watson

IBM Micromedex®

[我的訂閱](#) | [開道](#) | [Training Center](#) | [說明](#) | [下載中心](#) | [登出](#)

wafarin



主頁	藥物相互作用	IV 相容性	藥物鑒定	藥物比較	CareNotes	NeoFax® / Pediatrics	Tox 和藥物產品查找	其他工具 ▼
--------------------	------------------------	------------------------	----------------------	----------------------	---------------------------	--------------------------------------	-----------------------------	------------------------

列印

關於以下項的搜尋 "wafarin" 與任何文件均不相符。

您要尋找的是不是 **warfarin**, farin, nafarin, marfarin, afrin

© Copyright IBM Corporation 2022 | [關於](#) | [聯絡資訊](#) | [Training Center](#) | [使用者指南](#) | [保修與免責聲明](#) | [Micromedex.com](#)

Warfarin- FDA Uses


1. 考量問題：此藥物的適應症為何？

Home | Drug Interactions | IV Compatibility | Drug ID | Drug Comparison | CareNotes | NeoFax / Pediatrics | Other Tools ▾

WARFARIN [Your search: Warfarin]

Drug Classes: [Anticoagulant](#) | [Blood Modifier Agent](#) | [All](#)

Routes: [Intravenous](#) | [Oral](#)

Regulatory Authority: 

Quick Answers | **In-Depth Answers** | All Results


Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS

Dosing/Administration

FDA Uses 

See 'Quick Answers' for summary results.

Warfarin Sodium

- [Atrial fibrillation - Thromboembolic disorder](#)
- [Atrial fibrillation - Thromboembolic disorder: Prophylaxis](#)
- [Myocardial reinfarction; Prophylaxis](#)
- [Prosthetic cardiac valve component embolism](#)
- [Prosthetic cardiac valve component embolism; Prophylaxis](#)
- [Pulmonary embolism](#)
- [Pulmonary embolism; Prophylaxis](#)
- [Thrombosis, Post myocardial infarction; Prophylaxis](#)
- [Venous thromboembolism](#)
- [Venous thromboembolism; Prophylaxis](#)

Atrial fibrillation - Thromboembolic disorder

FDA Labeled Indication

a) Overview

FDA Approval: Adult, yes; Pediatric, no

Efficacy: Adult, Effective

Recommendation: Adult, Class I

View Full Document

Print

Related Results

- [Disease](#)
- [Toxicology](#)

- [Consumer Drug Information](#)
- [Drug Consults](#)
- [Index Nominum](#)
- [IT- Dialogo Sui Farmaci](#)
- [Martindale](#)
- [PDR®](#)
- [Product Lookup - Martindale](#)
- [Product Lookup - RED Book](#)
- [Product Lookup - Tox & Drug](#)

FDA Uses

Merative Micromedex®

我的訂閱 | 關道 | Training Center | 說明 | 下載中心 | 登出

wafarin



主頁	藥物相互作用	IV 相容性	藥物鑒定	藥物比較	CareNotes	NeoFax® / Pediatrics	Tox 和藥物產品查找	RED BOOK	計算器
----	--------	--------	------	------	-----------	----------------------	-------------	----------	-----

- Drug Properties
- Storage & Stability
- Trade Names
- Regulatory Status
- References

See Drug Consult reference: [Antithrombotic and Thrombolytic Therapy in Children and Neonates - ACCP Guidelines](#)
See Drug Consult reference: [Atrial Fibrillation - Drug Treatment Guidelines](#)

Atrial fibrillation - Thromboembolic disorder; Prophylaxis
 FDA Labeled Indication
 a) Overview
 FDA Approval: Adult, yes; Pediatric, no
 Efficacy: Adult, Effective
 Recommendation: Adult, Class IIa
 Strength of Evidence: Adult, Category A
 See Drug Consult reference: [RECOMMENDATION AND EVIDENCE RATINGS](#)

是否為核准的適應症用藥？
有建議強度與證據等級嗎？

b) Summary:

Product Availability

The marketing and distribution of warfarin sodium for injection has been discontinued as of 5/2/2014 [15]

Indication

Warfarin is indicated for the prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation [14].


Limitations of Use

Warfarin has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae [14].

Evidence (Nonvalvular Atrial Fibrillation)

Direct thrombin inhibitors (DTIs) were similar to adjusted-dose warfarin (INR target, 2 to 3) for reduction in the composite of vascular deaths and ischemic events or composite of stroke, systemic embolic (S/SE) event, MI, and cardiovascular mortality in patients with nonvalvular AF who had 1 or more risk factors for stroke in a meta analysis, and a randomized study of patients underlying electrical cardioversion [16][17]. No significant bleeding differences were observed between warfarin and edoxaban [17]; however, the addition of aspirin to oral anticoagulants significantly increased risk of major bleeding events and hospitalizations related to bleeding [18]. The estimated annual event rate for ischemic stroke and risk of intracranial hemorrhage (ICH) events were lowest for target INR between 2 to 2.5 compared to other INR ranges according to pooled data from 3 large, randomized trials of patients with nonvalvular atrial fibrillation receiving warfarin. Additionally,

Feedback



檢視證據等級與建議強度

RECOMMENDATION, EVIDENCE AND EFFICACY RATINGS

列印

藥物諮詢

頁首

RESPONSE

The Micromedex Efficacy, Strength of Evidence and Strength of Recommendation definitions are outlined below:

Table 1. Strength Of Recommendation

Class I	Recommended	The given test or treatment has been proven to be useful, and should be performed or administered.
Class IIa	Recommended, In Most Cases	The given test, or treatment is generally considered to be useful, and is indicated in most cases.
Class IIb	Recommended, In Some Cases	The given test, or treatment may be useful, and is indicated in some, but not most, cases.
Class III	Not Recommended	The given test, or treatment is not useful, and should be avoided.
Class Indeterminate	Evidence Inconclusive	

Table 2. Strength Of Evidence

Category A	Category A evidence is based on data derived from: Meta-analyses of randomized controlled trials with homogeneity with regard to the directions and degrees of results between individual studies. Multiple, well-done randomized clinical trials involving large numbers of patients.
Category B	Category B evidence is based on data derived from: Meta-analyses of randomized controlled trials with conflicting conclusions with regard to the directions and degrees of results between individual studies. Randomized controlled trials that involved small numbers of patients or had significant methodological flaws (e.g., bias, drop-out rate, flawed analysis, etc.). Nonrandomized studies (e.g., cohort studies, case-control studies, observational studies).
Category C	Category C evidence is based on data derived from: Expert opinion or consensus, case reports or case series.
No Evidence	

Therapeutic Uses

2. 考量問題：使用抗凝血藥物是否可顯著降低中風危險？

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

FDA Labeled Indication

a) Overview

FDA Approval: Adult, yes; Pediatric, no

Efficacy: Adult, Effective

Recommendation: Adult, Class I

Strength of Evidence: Adult, Category A

See Drug Consult reference: [RECOMMENDATION AND EVIDENCE RATINGS](#)

Evidence (Elderly)

Adjusted-dose warfarin significantly reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and arterial embolism among patients 75 years or older with chronic AF or atrial flutter compared with aspirin [15]. The recurrence of hemorrhagic events showed variable results; there were no significant differences on extracranial hemorrhage in elderly patients [15].

4) Elderly

a) Adjusted-dose warfarin reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and other clinically significant arterial embolism compared with aspirin 75 mg/day, among patients 75 years or older with chronic atrial fibrillation or atrial flutter, with no significant difference on major extracranial hemorrhage (BAFTA; N=973) [15].

Summary :
療效與出血風險

詳細說明的建議有...

檢視
資訊來源

Evidence (Elderly)

Adjusted-dose warfarin significantly reduced the incidence of the composite endpoint of fatal and nonfatal disabling stroke (ischemic or hemorrhagic), intracranial hemorrhage, and arterial embolism among patients 75 years or older with chronic AF or atrial flutter compared with aspirin [15]. The recurrence of hemorrhagic events showed variable results; there were no significant differences on extracranial hemorrhage in elderly patients [15].

References

[15] Mant J, Hobbs R, Fletcher K, et al: Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493-503.

PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>

PubMed Article: <http://www.ncbi.nlm.nih.gov/...>

關閉

Adverse Reactions

3. 考量問題：使用抗凝血藥物可能的副作用？

The screenshot displays a web-based medical database interface. At the top, there is a navigation bar with tabs for '主頁', '藥物相互作用', 'IV 相容性', '藥物鑒定', '藥物比較', 'CareNotes@', 'NeoFax@ / Pediatrics', and '其他工具'. The main content area is divided into three columns. The left column contains a sidebar menu with categories like 'Adult Dosing', 'Pediatric Dosing', 'FDA Uses', 'Non-FDA Uses', 'Dose Adjustments', 'Administration', 'Comparative Efficacy', 'Place In Therapy', 'Medication Safety', 'Contraindications', 'Precautions', 'Adverse Effects', 'Black Box Warning', 'REMS', 'Drug Interactions (single)', 'IV Compatibility (single)', 'Pregnancy & Lactation', 'Monitoring', and 'Do Not Confuse'. The middle column is titled 'Adverse Effects' and includes a '列印' (Print) icon. It lists various effect categories: 'Cardiovascular Effects', 'Dermatologic Effects', 'Endocrine/Metabolic Effects', 'Gastrointestinal Effects', 'Hematologic Effect' (highlighted with a yellow box), 'Hepatic Effects', 'Immunologic Effects', 'Musculoskeletal Effects', 'Neurologic Effects', 'Ophthalmic Effects', 'Renal Effects', 'Reproductive Effects', 'Respiratory Effects', and 'Other'. Below this, 'Cardiovascular Effects' is also highlighted with a yellow box, listing 'Warfarin Sodium', 'Cholesterol embolus syndrome', 'Gangrenous disorder', 'Hemopericardium', and 'Vasculitis'. A callout box points to the 'Hematologic Effects' section, listing 'Warfarin Sodium', 'Anemia', 'Blood coagulation disorder', 'Eosinophil count raised', 'Hemolytic anemia', and 'Hemorrhage Summary'. The right column is titled '毒理學 疾病' (Toxicology Diseases) and lists resources such as 'Drug Consults', 'eMC SmPC (UK)', 'Index Nominum', 'IT- Dialogo Sui Farmaci', 'Martindale', 'PDR@', 'Product Lookup - Martindale', 'Product Lookup - RED Book Online', 'Product Lookup - Tox & Drug', and '消費者藥物資訊'. A blue square icon with a white triangle is located at the bottom right of the page.

Adverse Reactions

Hemorrhage

出血的危險因子

c) Summary

1) Risk factors for major or fatal bleeding in patients taking warfarin sodium include a higher starting INR, age 65 years or older, variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs, and long duration of warfarin therapy [116]. Other risk factors for a major bleed occurring during warfarin anticoagulation are comorbid conditions, atrial fibrillation, and the first 90 days of warfarin therapy [123][124][125]. Regular monitoring of INR should be performed on all patients. More frequent monitoring, careful dose adjustment, and a shorter duration of therapy may be warranted in patients at high risk for bleeding [116].

b) Prevention and Management

- 1) Perform regular (ie, generally every 1 to 4 weeks) INR monitoring in all treated patients [116]
- 2) Consider more frequent INR monitoring, careful dose titration to desired INR, and shortest possible therapy duration in high-risk patients [116]
- 3) Monitor INR more frequently with treatment initiation, dose adjustment, or withdrawal of other drugs (including botanicals) [116]
- 4) Determine INR immediately before any dental or surgical procedure [116]
- 5) Adjust the dose to maintain INR on the low end of the therapeutic range to continue anticoagulation in patients undergoing minimally invasive procedures [116]
- 6) Do not routinely base vitamin K antagonist (ie, warfarin) therapy interruption solely on clinical prediction rules for bleeding [3].
- 7) If the timeline for anticoagulant reversal is more than 24 hours, interrupt therapy. Oral or parenteral vitamin K may be administered if necessary [116] based on INR [147]
- 8) If expedited (ie, within 1 to 24 hours), oral or parenteral vitamin K(1) may be administered if necessary [116]
- 9) If emergent (ie, within less than 1 hour), oral or parenteral vitamin K(1) may be administered if necessary [116]. Consider high-dose concentrates (eg, 4-factor prothrombin complex concentrate, 3-factor prothrombin complex concentrate, activated prothrombin complex concentrate, recombinant factor VIIa, or fresh frozen plasma) [116][147]
- 10) The following are evidence-based guidelines from the American College of Chest Physicians for managing elevated INR or bleeding in patients on vitamin K antagonist (ie, warfarin) therapy:
 - a) INR between 4.5 and 10 with no evidence of bleeding:
 - 1) Routine use of vitamin K is not recommended [3].
 - b) INR greater than 10 with no evidence of bleeding:
 - 1) Administer oral vitamin K [3].
 - c) Vitamin K antagonist-associated major bleeding:
 - 1) Instead of plasma use, achieve rapid anticoagulation reversal with 4-factor prothrombin complex concentrate. Coadminister with vitamin K 5 to 10 mg via slow IV injection rather than attempting reversal with coagulation factor alone [3].

預防與管理： 針對不良反應之處理建議

Monitoring

5. 考量問題：使用抗凝血藥物須監測的項目/頻率？

Dosing/Administration

Adult Dosing
Pediatric Dosing
FDA Uses
Non-FDA Uses
Dose Adjustments
Administration
Comparative Efficacy
Place In Therapy

Medication Safety

Contraindications
Precautions
Adverse Effects
Black Box Warning
REMS
Pregnancy & Lactation

Monitoring

Medication Safety

Monitoring

請參閱 ['簡要解答'](#) 瞭解綜述結果。

A) Warfarin Sodium

1) Therapeutic

a) Laboratory Parameters

1) INR

a) Monitor INR daily following the initial warfarin dose until the INR stabilized to the therapeutic range; then periodically based on clinical need, generally every 1 to 4 weeks. Perform additional INR testing when other warfarin products are interchanged with Coumadin(R) or when other drugs (including botanicals) are initiated, discontinued, have dosages changed, or taken irregularly. patients with a high risk of bleeding may require more frequent INR monitoring (manufacturer) [2].

b) Monitor INR up to every 12 weeks in patients with consistently stable INRs, defined as at least **3 months** of consistent results with no need to adjust warfarin dosing. Evaluate the INR within 1 to 2 weeks if the patient experiences a single out of range value, below or above the therapeutic INR by 0.5 or less (American College of Chest Physicians guidelines) [1]

In general, the recommended target INR is 2.5 (range, 2 to 3) in adults and pediatric patients in most indications [112][1], except in the following situations:

Target INR is 3 (range 2.5 to 3.5):

 檢視完整文件

 列印

監測項目與
監測頻率

相關結果

毒理學
疾病

Drug Consults
eMC SmPC (UK)
Index Nominum
IT- Dialogo Sui Farmaci
Martindale
PDR®
Product Lookup - Martindale
Product Lookup - RED Book Online
Product Lookup - Tox & Drug
消費者藥物資訊

達到穩定狀態後的
建議監測頻率

Patient Handouts

6. 考量問題：如何進行用藥指導？

Monitoring	<p><u>Drugs and Foods to Avoid:</u> Ask your doctor or pharmacist before using any other medicine, including over-the-counter medicines, vitamins, and herbal products.</p> <p>Many medicines and foods can affect how warfarin works and may affect the PT/INR test results. Tell your doctor before you start or stop any medicine, especially the following:</p> <p>Co-enzyme Q10, echinacea, garlic, ginkgo, ginseng, goldenseal, or St John's wort Another blood thinner, including apixaban, argatroban, bivalirudin, cilostazol, clopidogrel, dabigatran, desirudin, dipyridamole, heparin, lepirudin, prasugrel, rivaroxaban, ticlopidine Medicine to treat depression or anxiety, including citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone Medicine to treat an infection NSAID pain or arthritis medicine, including aspirin, celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac. Check labels for over-the-counter medicines to find out if they contain an NSAID. Steroid medicine, including dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone</p>
Do Not Confuse	
Mechanism of Action	
Mechanism of Action	
Pharmacokinetics	
Pharmacokinetics	
Patient Education	
Medication Counseling	
Patient Handouts	
Toxicology	
Clinical Effects	

查找疾病資訊

輸入症狀或疾病名

搜尋疾病

[全部](#) |
 [藥物](#) |
 [疾病](#) |
 [毒理學](#)

Heart fa



- Heart failure**
- Heart failure, acute**
- Heart failure, acute; Congestive heart failure**
- Heart failure, chronic**
- Heart failure, chronic; Congestive heart failure**
- Acute congestive **heart failure**
- Acute exacerbation of chronic congestive **heart failure**
- Acute **heart failure**

- [Citing Micromedex](#)

Read Top News



Support Request



資源

- [黑框警告](#)
- [Comparative Tables](#)
- [Do Not Confuse Drug List](#)
- [Drug Classes](#)
- [Drug Consults](#)
- [REMS](#)



Download Mobile Apps

Feedback

Micromedex Assistant

Search Micromedex drug information

Type a quick question... →

[Learn more](#)

3263 找到以下項的結果：“heart failure”

全部結果

篩選依據

全部 (10)

藥物 (3)

疾病 (7)

1-10 / 10 以下項目的結果 "Heart failure, acute; Congestive heart failure"

列印

[Heart failure, acute; Congestive heart failure](#)

Disease: Detailed evidence-based information

[Heart failure, acute; Congestive heart failure](#)

Disease: Summary topic

[Heart failure, acute; Congestive heart failure](#)

Disease: List of essential care interventions (*Clinical Checklist*)

[Heart failure, acute; Congestive heart failure - Prevention & Screening](#)

Disease: Detailed evidence-based information

[Heart failure, acute; Congestive heart failure - Prevention & Screening](#)

Disease: Summary topic

[Heart failure, chronic; Congestive heart failure - Prevention & Screening](#)

Disease: Detailed evidence-based information

Conditions [Heart failure, acute; Congestive heart failure - Acute Heart failure, acute; Congestive heart failure - Prevention Screening Heart...](#)

[Heart failure, chronic; Congestive heart failure](#)

Disease: Detailed evidence-based information

Depression - Chronic Diabetes mellitus - Chronic [Heart failure, acute; Congestive heart failure - Acute Heart failure, acute; Congestive heart failure - Prevention Screening Heart...](#)

[MILRINONE](#)

Drug: Detailed evidence-based information

Feedback

Ask Watson

Heart failure, acute; Congestive heart failure

簡要解答

深入解答

全部結果

Definition

Medical History

Findings

Differential Diagnosis

Testing

Treatment

Drug Therapy

Procedural Therapy

Reference

Testing

請參閱 '深入解答' 瞭解詳細結果。

 列印

Suspected or known heart failure [1][2][3][4]

- 12 lead ECG: In patients with heart failure, a 12-lead ECG is frequently abnormal [3] and may show evidence of ischemia, myocardial infarction, left ventricular hypertrophy, cardiac conduction abnormality, or cardiac arrhythmia [5].

Suspected, acute or new-onset heart failure [1]

- Plain chest X-ray: A chest x-ray assess cardiomegaly and pulmonary congestion and may identify alternative causes of symptoms, but should not be the sole determinant of the specific cause of heart failure. A normal chest x-ray does not exclude acutely decompensated heart failure [1].

Suspected or known heart failure [6]

- Brain natriuretic peptide measurement: Acute heart failure is likely in the presence of acute dyspnea if the B-type natriuretic peptide (BNP) level is greater than 500 picogram/mL or NT-proBNP is greater than 1000 picogram/mL and is unlikely if BNP is less than 100 picogram/mL or NT-proBNP is less than 300 picogram/mL [7]. Although levels vary, these cutoff values may still be useful to assess decompensation of chronic heart failure [8].

Suspected or known heart failure [1][2][9][4][3].

- Two dimensional echocardiography: All patients presenting with heart failure should receive echocardiographic evaluation of left ventricular ejection fraction, left and right ventricular size and function, ventricular wall thickness, valve function, and pericardial pathology [1][2][9][4][3].

相關結果

Disease Other Titles

臨床檢查表單

Feedback



Ask Watson



Heart failure, acute; Congestive heart failure

簡要解答

深入解答

全部結果

Definition

Medical History

Findings

Differential Diagnosis

Testing

Treatment

Drug Therapy

Procedural Therapy

Reference

Testing

請參閱 '深入解答' 瞭解詳細結果。

Suspected or known heart failure [1][2][3][4]

- 12 lead ECG: In patients with heart failure, a 12-lead ECG may identify alternative causes of symptoms, such as myocardial infarction, left ventricular hypertrophy, cardiac conduction abnormalities, and bundle branch block [1].

Suspected, acute or new-onset heart failure [1]

- Plain chest X-ray: A chest x-ray assess cardiomegaly and pulmonary congestion and may identify alternative causes of symptoms, but should not be the sole determinant of the specific cause of heart failure. A normal chest x-ray does not exclude acutely decompensated heart failure [1].

Suspected or known heart failure [6]

- Brain natriuretic peptide measurement: Acute heart failure is likely in the presence of acute dyspnea if the B-type natriuretic peptide (BNP) level is greater than 500 picogram/mL or NT-proBNP is greater than 1000 picogram/mL and is unlikely if BNP is less than 100 picogram/mL or NT-proBNP is less than 300 picogram/mL [7]. Although levels vary, these cutoff values may still be useful to assess decompensation of chronic heart failure [8].

Suspected or known heart failure[1][2][9][4][3].

- Two dimensional echocardiography: All patients presenting with heart failure should receive echocardiographic evaluation of left ventricular ejection fraction, left and right ventricular size and function, ventricular wall thickness, valve function, and pericardial pathology [1][2][9][4][3].

臨床檢查表單

- Heart failure, acute; Congestive heart failure

列印

關閉

相關結果

Disease Other Titles
臨床檢查表單

Feedback

Ask Watson

ALWAYS DO

- Diagnosis
- Treatment
- Disposition

RELATED INFORMATION

- Conditions
- Tests & Procedures

REFERENCES

Heart failure, acute; Congestive heart failure

Clinical Checklist

列印

全部展開 | 全部折疊 | 頁首

▼ Always Do

Diagnosis

Diagnostic Testing

	建議/證據強度	效能測量
Obtain a 12-lead ECG and chest radiographs (posteroanterior and lateral) in all patients presenting with heart failure [1].		
In a patient presenting with heart failure, obtain a 2-dimensional echocardiogram with Doppler to assess left ventricular ejection fraction, left ventricular size, wall thickness, and valve function [1].		
In patients who present with dyspnea, measure blood levels of B-type natriuretic peptide (BNP) or N-terminal-proBNP (NT-proBNP) to support or exclude a diagnosis of heart failure *142[2].		
In the initial evaluation of patients with acute heart failure, include CBC, urinalysis, serum electrolytes with calcium and magnesium, BUN, serum creatinine, fasting blood glucose or HbA1C, fasting lipid profile, liver function test panel, and TSH assay [1].		

Clinical Examination


	建議/證據強度	效能測量
Perform a thorough history and physical examination in patients presenting with heart failure (HF) to identify cardiac and noncardiac disorders or behaviors that might cause or accelerate the progression of HF [1].		

Feedback

工具好幫手

主頁	藥物 相互作用	IV 相容性	藥物 鑒定	藥物 比較	CareNotes	NeoFax [®] / Pediatrics	其他工具 ▼
----	------------	--------	----------	----------	-----------	-------------------------------------	--------

藥物相互作用



藥物相互作用

在搜尋欄位鍵入藥物名稱（品牌或學名藥）。選擇藥物並按一下 **+**（新增）按鈕。

輸入搜尋詞:

相符的藥物名稱: (21)

- Bilberry**
- Bilberry (Bilberry Extract)
- Bilberry (Bilberry/Vitamin A/Vitamin E...
- Bilberry (Homeopathic Substance)
- Bilberry (Whortleberry)
- Bilberry Extra Strength
- Bilberry Extract
- Bilberry Extract (Beta Carotene/Bilber...
- Bilberry Extract (Bilberry Extract/Bio...
- Bilberry Extract (Bilberry)
- Bilberry Extract/Bioflavonoid/Querceti...

保健食品：
歐越莓/
山桑子/
覆盆子

要檢查的藥物：

- Bilberry
- Ibuprofen
- Warfarin

日常用藥：
止痛藥

治療用藥：
AF, 高血壓

添加過敏

添加過敏

帶有星號 (*) 的字母大寫項目表示過敏。

清除 提交

新增過敏症狀。

在搜尋欄位中鍵入過敏症狀。選擇過敏症狀並按一下 (新增) 按鈕。
按一下「更新」將您的選擇加入至「藥物相互作用」中「要檢查的藥物」表單。

輸入過敏症狀:

asp

相符的過敏症狀: (7)

ASPARAGINASE
ASPARAGINE
ASPARAGUS
ASPARTIC ACID
ASPERGILLUS FUMIGATUS
ASPIRIN INTOLERANCE
ASPIRIN

要檢查的過敏症狀:

ASPIRIN
SEAFOOD

取消

更新

選擇藥物並按一下 (新增) 按鈕。

添加過敏

要檢查的藥物:

添加過敏

Bilberry
Ibuprofen
Warfarin
ASPIRIN*
SEAFOOD*

Bilberry Extra Strength
Bilberry Extract
Bilberry Extract (Beta Carotene/Bilber...
Bilberry Extract (Bilberry Extract/Bio...
Bilberry Extract (Bilberry)
Bilberry Extract/Bioflavonoid/Querceti...

帶有星號 (*) 的字母大寫項目表示過敏。

清除

提交

Drug Interaction Results

← 修改相互作用

列印

細化方式： 藥物： All 嚴重性： All 文件： All 類型： All

跳轉到： 藥物-藥物 (2) | 複方 (0) | 過敏症狀 (1) | 食物 (12) | 乙醇 (1) | 實驗室 (1) | 抽煙 (1) | 懷孕 (2) | 哺乳期 (2)

Drug-Drug 相互作用 (2)

藥物：

IBUPROFEN -- WARFARIN SODIUM

嚴重性
等級不同

嚴重性：

 Major

文件：

Fair

綜述：

Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.

BILBERRY -- WARFARIN SODIUM

 Moderate

Fair

Concurrent use of BILBERRY and ANTICOAGULANTS may result in increased risk of bleeding.

複方 (未找到)

Warfarin分別和Ibuprofen、歐越莓
併用皆會增加出血風險

Drug-過敏症狀 相互作用 (1)

藥物：

IBUPROFEN -- ASPIRIN

嚴重性：

 Unknown

文件：

Unknown

綜述：

CROSS-REACTIVITY MAY OCCUR AMONG NSAIDS, AND BETWEEN NSAIDS AND SALICYLATES (ASPIRIN).

Drug-食物 相互作用 (12)

Ask Watson

定義

嚴重性：



禁忌

禁止同時使用這些藥物。



嚴重

這種相互作用可能危及生命和/或需要醫療干預以儘量減少或避免嚴重的不良影響。



中等

這種相互作用可能導致加重患者的病情和/或需要在治療中發生改變。



較弱

這種相互作用將限制臨床效果。表現可能包括增加副作用的頻率或嚴重程度，但一般不需要在治療中發生重大改變。



未知

未知。

INTERACTION DETAIL

Warning:

Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.

Clinical Management:

Coadministration of an anticoagulant and an NSAID may increase the risk of serious bleeding relative to the use of either drug alone (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016; Prod Info COUMADIN® oral tablets, intravenous injection powder for solution, 2015) and may increase the risk of epidural or spinal hematomas that can result in long-term or permanent paralysis in patients who are receiving neuraxial anesthesia or undergoing spinal puncture (Prod Info PRADAXA® oral capsules, 2015; Prod Info SAVAYSA(TM) oral tablets, 2015). If used concomitantly, monitor for signs of bleeding (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016).

Onset:

Not Specified

INTERACTION DETAIL

Major

Documentation:

Fair

Probable Mechanism:

additive effect on hemostasis

Summary:

Coadministration of an anticoagulant and an NSAID may increase the risk of serious bleeding relative to the use of either drug alone (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016; Prod Info COUMADIN® oral tablets, intravenous injection powder for solution, 2015) and may increase the risk of epidural or spinal hematomas that can result in long-term or permanent paralysis in patients who are receiving neuraxial anesthesia or undergoing spinal puncture (Prod Info PRADAXA® oral capsules, 2015; Prod Info SAVAYSA(TM) oral tablets, 2015). If used concomitantly, monitor for signs of bleeding (Prod Info CALDOLOR® intravenous injection, 2016; Prod Info CELEBREX® oral capsules, 2016).

列印  關閉 

細化方式： 藥物： All 嚴重性： 2 (Selected) 文件： All 類型： All

跳轉到： 藥物-藥物 (1) | 食物 (2) | 抽煙 (1) | 哺乳期 (1)

Drug-Drug 相互作用 (1)			
藥物：	嚴重性：	文件：	綜述：
IBUPROFEN – WARFARIN SODIUM	Major	Fair	Concurrent use of NSAIDs may result in increased risk of bleeding.
Drug-食物 相互作用 (2)			
藥物：	嚴重性：	文件：	綜述：
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.
Drug-抽煙 相互作用 (1)			
藥物：	嚴重性：	文件：	綜述：
WARFARIN SODIUM	Major	Fair	Concurrent use of CYP1A2 SUBSTRATES and TOBACCO may result in decreased exposure of CYP1A2 substrates.
Drug-哺乳期 相互作用 (1)			
藥物：	嚴重性：	文件：	綜述：
IBUPROFEN	Major	Unknown	Infant risk cannot be ruled out. Available evidence and/ or expert consensus is inconclusive or is inadequate for determining infant risk when Ibuprofen is used during breast-feeding. Weigh the potential benefits of treatment against potential risks before prescribing Ibuprofen during breast-feeding.

選中/取消選中以細化嚴重性設定。

全部選中 | 全部不選

Contraindicated

Major

Moderate

Minor

Unknown

取消 更新

定義

嚴重性： 禁忌 嚴重 中等 較弱 未知

文件： 卓越 良好 一般 未知



多個藥物的IV相容性

IV 相容性

Add at least one drug and press View Compatibility

Drugs (1668)



Select Drug(s) to view Drug-Drug IV Compatibility



輸入至少一種藥品

Lorazepam ×

Palonosetron hydrochloride ×

預防化療引起的
噁心嘔吐

Solutions (257) *optional



Select Solution(s) to view Drug-Solution IV Compatibility



需要時輸入溶液

Clear All

View Compatibility

NOTE: IV Compatibility for Drug - Drug Compatibility is displayed in drug pairs

由 Trissel's™ 2 Clinical Pharmaceutics Database (Parenteral Compatibility). 支援。

治療焦慮、化療
引起的噁心嘔吐



多個藥物的IV相容性

IV 相容性結果 ◀ 修改相容性


Key :     

Preparation and Storage
Click to view Product and Storage Information

Drugs

-  Lorazepam
-  Palonosetron hydrochloride

Drug-Solution |
 Drug-Drug: Y-Site |
 Drug-Drug: Admixture |
 Drug-Drug: Syringe |
 相容性 : All

Y-Site Results Summary (View Compatibility Details)	Status
Lorazepam - Palonosetron hydrochloride	 相容

Filter Results

全部選中 | 全部不選

Drugs

- Lorazepam
- Palonosetron hydrochloride

取消 更新

Tip: To see additional information on TPN/TNA compatibility, select a single drug from the list and choose Update.

單一藥物的IV相容性



IV 相容性結果

◀ 修改相容性

Key :     

Preparation and Storage
Click to view Product and Storage Information

Drugs

-  Lorazepam
-  Palonosetron hydrochloride








Filter Results

全部選中 | 全部不選

Drugs

- Lorazepam
- Palonosetron hydrochloride

取消 更新

Drug-Solution	Y-Site	Admixture	Syringe	TPN/TNA	相容性 :
Y-Site Results Summary (View Compatibility Details)					
					All
Y-Site Results Summary (View Compatibility Details)					Status
Acetaminophen					 相容
Acyclovir sodium					 相容
Alatrofloxacin mesylate					 相容
Albumin Human					 相容
Aldesleukin					 不相容
Alemtuzumab					 相容
Alfentanil hydrochloride					 相容

單一藥物的IV相容性 - TPN / TNA

IV 相容性結果

← 修改相容性

Key :     

Preparation and Storage
Click to view Product and Storage Information

Drugs

- [Lorazepam](#)
- [Palonosetron hydrochloride](#)


Filter Results

全部選中 | 全部不選

Drugs

- Lorazepam
- Palonosetron hydrochloride

取消 更新

Drug-Solution	Y-Site	Admixture	Syringe	TPN/TNA	相容性 : All
<p>TPN (2-in-1) Results Summary Status</p> <p>注意 : Two TPN formulas (peripheral-line and central-line formulas) based on Aminosyn II were evaluated for compatibility with the test drug.</p> <p>(1) The peripheral-line formula had the following composition per liter: Aminosyn II 3.5% Dextrose 5% Sterile water for injection 517 mL Sodium chloride 25 mEq Potassium chloride 35 mEq Potassium phosphates 3.5 mmol Magnesium sulfate 8 mEq Calcium gluconate 9.3 mEq M.V.I.-12 10 mL Trace elements</p> <p>(2) The central-line formula had the following composition per liter: Aminosyn II 4.25% Dextrose 25% Sterile water for injection 161 mL Sodium chloride 25 mEq Potassium chloride 18 mEq Potassium phosphates 15 mmol Magnesium sulfate 8 mEq Calcium gluconate 9.15 mEq M.V.I.-12 10 mL</p> <p>0.1 mg/mL</p> <p style="text-align: right;"> 相容 Y-Site</p>					

藥物鑒定 用印碼查詢



Drug Identification

Search: by Imprint Code | [No Imprint Code? Click here to search by Description](#) ▶

Side 1:	<input type="text" value="mrk"/>	<input checked="" type="checkbox"/> Partial Imprint
Side 2:	<input type="text" value="7"/>	<input checked="" type="checkbox"/> Partial Imprint

© Copyright IBM Corporation 2018 | [About](#) | [Contact](#) | [Training Center](#) | [User Guide](#) | [Warranty & Disclaimer](#) | [Micromedex.com](#)

藥物鑒定 印碼查找結果

Home | Drug Interactions | IV Compatibility | **Drug ID** | Drug Comparison | CareNotes | NeoFax / Pediatrics | Other Tools ▾

Drug Identification Results

6 Matches for: "mrk, 7" Sort all Results by:

6 Drug Matches for 'M' 1 - 6 (of 6 matching drugs) ◀◀ First ◀ Previous | Next ▶ Last ▶▶

Display: [ALL](#) | [0-9](#) | [A](#) | [B](#) | [C](#) | [D](#) | [E](#) | [F](#) | [G](#) | [H](#) | [I](#) | [J](#) | [K](#) | [L](#) | **M** | [N](#) | [O](#) | [P](#) | [Q](#) | [R](#) | [S](#) | [T](#) | [U](#) | [V](#) | [W](#) | [X](#) | [Y](#) | [Z](#)

Imprint ▾	Drug Name	Manufacturer	Availability	AAPCC	Poisindex Managements
MRK 711 Singulair	Singulair	Merck Sharp & Dohme	United States	201078	MONTELUKAST
MRK 717 HYZAAR	Hyzaar 50-12.5	Merck Sharp & Dohme	United States	310109	ANGIOTENSIN II ANTAGONISTS DIURETICS
MRK 747 HYZAAR	Hyzaar 100-25	Merck Sharp & Dohme	United States	310109	ANGIOTENSIN II ANTAGONISTS DIURETICS
Mrk; 717	Hyzaar	Merck Frosst	Canada	310109	ANGIOTENSIN II ANTAGONISTS DIURETICS
Mrk; 74; Vioxx	Vioxx	Merck Frosst	Canada	201065	COX-2 INHIBITORS
Mrk; 74; Vioxx	Vioxx	Merck & Company	United States	201065	COX-2 INHIBITORS

藥物鑒定 印碼查找結果

DRUG INFORMATION

Tox & Drug: [Hyzaar 100-25 ▶](#)
 Martindale: [Hyzaar 100-25 ▶](#)

DRUG NAME: HYZAAR 100-25
INGREDIENTS: HYDROCHLOROTHIAZIDE -- 25 MG
 LOSARTAN -- 100 MG

RELATED DOCUMENTS: [POISINDEX MANagements - ANGIOTENSIN II ANTAGONISTS](#)
[POISINDEX MANagements - DIURETICS](#)
[DRUGDEX EVALUATIONS - LOSARTAN](#)
[DRUGDEX EVALUATIONS - HYDROCHLOROTHIAZIDE](#)

COLOR: LIGHT YELLOW
SHAPE: TEARDROP-SHAPE
IMPRINT: HYZAAR , MRK 747
FORM: ORAL TABLET

AVAILABLE-CONTAINER-SIZE: BOTTLE OF 1000 ,
 BOTTLE OF 90 , STRIP OF 100 , BOTTLE OF 4000 ,
 BOTTLE OF 30

AAPCC CODE: 310109 - ANGIOTENSIN RECEPTOR BLOCKER IN COMBINATION WITH DIURETIC

NDC: 00006-0747-28
 00006-0747-81
 00006-0747-31
 00006-0747-82
 00006-0747-54

EXCIPIENTS: D&C YELLOW NO. 10 ALUMINUM LAKE ; HYDROXYPROPYL CELLULOSE ; HYPROMELLOSE ; LACTOSE, HYDROUS ; MAGNESIUM STEARATE ; MICROCRYSTALLINE CELLULOSE ; PREGELATINIZED STARCH

REGULATORY STATUS: RX
AVAILABILITY: UNITED STATES
PRODUCT ID 5724722

PRINT

藥物資訊

可用容器大小: BOTTLE OF 1000 , BOTTLE OF 90 , STRIP OF 100 , BOTTLE OF 4000 , BOTTLE OF 30

AAPCC 代碼: 310109 - ANGIOTENSIN RECEPTOR BLOCKER IN COMBINATION WITH DIURETIC

輔料: D&C YELLOW NO. 10 ALUMINUM LAKE ; HYDROXYPROPYL CELLULOSE ; HYPROMELLOSE ; LACTOSE, HYDROUS ; MAGNESIUM STEARATE ; MICROCRYSTALLINE CELLULOSE ; PREGELATINIZED STARCH

監管狀態: RX
 可用性: UNITED STATES
 產品 ID 5724722
 聯絡資訊: MERCK SHARP & DOHME



No Image Available

列印 關閉

藥物鑒定用外觀查詢



Drug Identification

Search: by Description [Click here to search by Imprint Code ▾](#)

- Black
- Blue
- Brown
- Clear
- Gold
- Gray
- Green
- Off-White
- Orange
- Pink
- Purple
- Red
- Tan
- White
- Yellow

Shape:

Pattern:

Show Images with results


© Copyright IBM Corporation 2018 | [About](#) | [Contact](#) | [Training Center](#) | [User Guide](#) | [Warranty & Disclaimer](#) | [Micromedex.com](#)

5 Matches for: "Egg-shape, All Patterns, Pink" Sort all Results by:

1 Drug Match for 'A' 1 - 1 (of 1 matching drugs) [◀First](#) [◀Previous](#) | [Next](#) [▶Last](#)▶

Display: [ALL](#) | [0-9](#) | **[A](#)** | [B](#) | [C](#) | [D](#) | [E](#) | [F](#) | [G](#) | [H](#) | [I](#) | [J](#) | [K](#) | [L](#) | [M](#) | [N](#) | [O](#) | [P](#) | [Q](#) | [R](#) | [S](#) | [T](#) | [U](#) | [V](#) | [W](#) | [X](#) | [Y](#) | [Z](#)

[Hide Images](#)

Image (US)	Imprint ▾	Drug Name
	AMOXIL 125	Amoxil

© Copyright IBM Corporation 2018 | [About](#) | [Contact](#) | [Training Center](#) | [User Guide](#) | [Warranty & Disclaimer](#) | [Micromedex.com](#)

藥物比較

Home Drug Interactions IV Compatibility Drug ID **Drug Comparison** CareNotes NeoFax / Pediatrics Other Tools ▾

Drug Comparison

Type the drug name (brand or generic) in the search field. Select the drug and click the ➤ (Add) button.

Enter search term:

Matching drug names: (2)

- Warfarin Na
- Warfarin Sodium

Drugs to check:

- Dabigatran Etexilate Mesylate
- Rivaroxaban
- Warfarin Sodium

Clear Submit

藥物比較(適應症)_證據等級

Home | Drug Interactions | IV Compatibility | Drug ID | **Drug Comparison** | CareNotes | NeoFax / Pediatrics | Other Tools ▾

Drug Comparison Results ◀ Modify Comparison

Display in Column 1: Warfarin Sodium | Display in Column 2: Dabigatran Etexilate Mesylate

Update

Jump To: [↑ Top of Page](#) | [Dosing & Indications](#) | [Black Box Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single\)](#) | [Adverse Effects](#) | [Name Info](#) | [Mechanism of Action/Pharmacokinetics](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#)

FDA-Labeled Indications	FDA-Labeled Indications
<p>View Detailed information in DRUGDEX ▶</p> <p>▶ Atrial fibrillation - Thromboembolic disorder FDA Approval:</p> <ul style="list-style-type: none"> Adult, yes Pediatric, no <p>Efficacy:</p> <ul style="list-style-type: none"> Adult, Effective 	<p>View Detailed information in DRUGDEX ▶</p> <p>▶ Atrial fibrillation - Thromboembolic disorder; Prophylaxis FDA Approval:</p> <ul style="list-style-type: none"> Adult, yes Pediatric, no <p>Efficacy:</p> <ul style="list-style-type: none"> Adult, Effective
<p>Strength of Recommendation:</p> <ul style="list-style-type: none"> Adult, Class I <p>▶ Strength of Evidence:</p> <ul style="list-style-type: none"> Adult, Category A 	<p>Strength of Recommendation:</p> <ul style="list-style-type: none"> Adult, Class IIa <p>▶ Strength of Evidence:</p> <ul style="list-style-type: none"> Adult, Category B
<p>Atrial fibrillation - Thromboembolic disorder; Prophylaxis FDA Approval:</p> <ul style="list-style-type: none"> Adult, yes Pediatric, no 	<p>Deep venous thrombosis, Following parenteral therapy FDA Approval:</p> <ul style="list-style-type: none"> Adult, yes Pediatric, no

藥物比較(不良反應)_一般/嚴重

Home | Drug Interactions | IV Compatibility | Drug ID | **Drug Comparison** | CareNotes | NeoFax / Pediatrics | Other Tools ▾

Drug Comparison Results

◀ Modify Comparison

Display in Column 1: Warfarin Sodium | Display in Column 2: Dabigatran Etexilate Mesylate

Update

Jump To: [↑ Top of Page](#) | [Dosing & Indications](#) | [Black Box Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single Action/Pharmacokinetics\)](#) | **Adverse Effects** | [Name Info](#) | [Mechanism of Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#)

Adverse Effects	Adverse Effects
View Detailed information in DRUGDEX ▶	View Detailed information in DRUGDEX ▶
Common <ul style="list-style-type: none">• Dermatologic: Alopecia	Common <ul style="list-style-type: none">• Gastrointestinal: Esophagitis, Gastritis, Gastroesophageal reflux disease (Atrial fibrillation, 5.5%), Gastrointestinal hemorrhage (DVT and pulmonary embolism, 0.7% to 3.1%; nonvalvular atrial fibrillation, 6.1%), Gastrointestinal ulcer, Indigestion (DVT and pulmonary embolism, 4.1% to 7.5%)• Hematologic: Hemorrhage (DVT and pulmonary embolism treatment or prophylaxis, 9.7% to 12.3%; nonvalvular atrial fibrillation, 16.6%)
Serious <ul style="list-style-type: none">• Cardiovascular: Cholesterol embolus syndrome, Tissue necrosis (Less than 0.1%)• Dermatologic: Calciphylaxis, Tissue necrosis (Less than 0.1%)• Hematologic: Hemorrhage, Hemorrhage• Immunologic: Hypersensitivity reaction• Musculoskeletal: Compartment syndrome• Neurologic: Intracranial hemorrhage	Serious <ul style="list-style-type: none">• Cardiovascular: Myocardial infarction (DVT and pulmonary embolism, 0.1% to 0.66%; nonvalvular atrial fibrillation, 0.7%)• Gastrointestinal: Gastrointestinal hemorrhage, Major (DVT and pulmonary embolism, 0.1% to 0.6%; nonvalvular atrial fibrillation, 1.6%)• Hematologic: Hemorrhage, Major (DVT and pulmonary embolism, 0.3% to 2%; nonvalvular atrial fibrillation, 3.3%), Thrombosis• Immunologic: Anaphylaxis• Neurologic: Epidural hematoma, Intracranial hemorrhage (Nonvalvular atria

藥物比較-切換另一藥物

Home | Drug Interactions | IV Compatibility | Drug ID | **Drug Comparison** | CareNotes | NeoFax / Pediatrics | Other Tools ▾

Drug Comparison Results ◀ Modify Comparison

Display in Column 1

Warfarin Sodium

Display in Column 2

- Dabigatran Etexilate Mesylate
- Dabigatran Etexilate Mesylate
- Rivaroxaban**
- Warfarin Sodium

Jump To: [↑ Top of Page](#) | [Dosing & Indications](#) | [Black Box Warning](#) | [Contraindications/Warnings](#) | [Drug Interactions \(single\)](#) | [Adverse Effects](#) | [Name Info](#) | [Mechanism of Action/Pharmacokinetics](#) | [Administration/Monitoring](#) | [How Supplied](#) | [Toxicology](#) | [Clinical Teaching](#) | [References](#)

Adverse Effects

[View Detailed information in DRUGDEX ▶](#)

Common

- **Dermatologic:** Alopecia

Serious

- **Cardiovascular:** Cholesterol embolus syndrome, Tissue necrosis (Less than 0.1%)
- **Dermatologic:** Calciphylaxis, Tissue necrosis (Less than 0.1%)
- **Hematologic:** Hemorrhage, Hemorrhage
- **Immunologic:** Hypersensitivity reaction
- **Musculoskeletal:** Compartment syndrome

Adverse Effects

[View Detailed information in DRUGDEX ▶](#)

Common

- **Gastrointestinal:** Esophagitis, Gastritis, Gastroesophageal reflux disease (Atrial fibrillation, 5.5%), Gastrointestinal hemorrhage (DVT and pulmonary embolism, 0.7% to 3.1%; nonvalvular atrial fibrillation, 6.1%), Gastrointestinal ulcer, Indigestion (DVT and pulmonary embolism, 4.1% to 7.5%)
- **Hematologic:** Hemorrhage (DVT and pulmonary embolism treatment or prophylaxis, 9.7% to 12.3%; nonvalvular atrial fibrillation, 16.6%)

Serious

- **Cardiovascular:** Myocardial infarction (DVT and pulmonary embolism, 0.1% to 0.66%; nonvalvular atrial fibrillation, 0.7%)
- **Gastrointestinal:** Gastrointestinal hemorrhage, Major (DVT and pulmonary embolism, 0.1% to 0.6%; nonvalvular atrial fibrillation, 1.6%)
- **Hematologic:** Hemorrhage, Major (DVT and pulmonary embolism, 0.3% to 2%; nonvalvular atrial fibrillation, 3.3%), Thrombosis
- **Immunologic:** Anaphylaxis

Calculators

Calculators

依種類

All Calculators

Alphabetical Order

By Category

Frequent Use Calculators

Unit and Dose Converters

Medical Equations

Clinical Criteria

Decision Trees

依專業

By Specialty

All Specialties

Pharmacology

Nursing

Medical Statistics

數學計算

Math Calculator

Math Calculator

About

Glossary

References

All Calculators

Alphabetical Order

Find a calculator

Or click a letter to jump to that section. Click on a link below to use a formula or criteria.

跳轉到: [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#) [0-9](#)

Displaying 690 calculators

A

- A-a Gradient
- a/A Ratio
- AaPO2 Correction for FIO2
- ABCD Rule Predicting Stroke Within 7 Days of a TIA
- ABCD2 Score to Predict Stroke Risk after TIA
- Absolute Eosinophil Count
- Absolute Lymphocyte Count
- Absolute Neutrophil Count

ACLS: Adult Emergency Drug Dosing Calculator

Input

Patient Name:

Weight*:

Patient

80 kg

- gm
- kg
- lb

輸入病患姓名

輸入體重

Create Dosing Table

Notes

- Use this calculator to generate a weight based dosing sheet for commonly used emergency medications.
- **Weight*** is a mandatory input.
- You must have *pop-ups* enabled to see and print the customized dosing sheet.
- Once you have entered the patient **Weight**, and any optional information, click the **Create Dosing Table** button and the customized sheet will appear in a new window. A print prompt will appear automatically.

ACLS: Adult Emergency Drug Dosing Calculator

80 kg

Date: 2022/7/25 下午4:57:03

Patient Name: Xi

Recommendations according to AHA guidelines ACLS resuscitation.

**Attention - Institutionally dispensed drug concentrations may vary.*

Drug	Concentration	Route	Dose
Adenosine			
6 mg	3 mg/mL	Rapid IV Push	6 mg (2 mL) over 1 to 3 seconds
May Repeat: 12 mg X 2 MAX: 30 mg	3 mg/mL	Rapid IV Push	May Repeat: after 1 to 2 minutes, 12 mg (4 mL) over 1 to 3 seconds; may repeat another 12 mg after 1 to 2 minutes MAX: 30 mg
Follow adenosine IV push with 20 mL saline flush. Higher doses may be required in patients taking theophylline.			

客製化的ACLS清單

Amiodarone: Stable VT			
150 mg	1.5 mg/mL	Slow IV Push	150 mg (10 mL/min) over 10 minutes
May Repeat: 150 mg	1.5 mg/mL	Slow IV Push	May Repeat: 150 mg
Mix 3 mL from a 50 mg/mL vial in 100 mL D5W for a 1.5 mg/mL solution.			
1 mg/min MAX Cumulative Dose: 2.2 g over 24 hours	1.8 mg/mL	Infusion	1 mg/min (33 mL/hr) for 6 hours, then 0.5 mg/min (16 mL/hr) MAX Cumulative Dose: 2.2 g over 24 hours
Mix 18 mL of 50 mg/mL vial in 500 mL D5W for a 1.8 mg/mL solution.			
Atropine sulfate: Bradycardia			
1 mg	0.1 mg/mL	IV Push	1 mg (10 mL)
May Repeat: 1 mg MAX Cumulative Dose: 3 mg	0.1 mg/mL	IV Push	May Repeat: 1 mg every 3 to 5 minutes
If manufacturer recommendation is unknown then use maximum available.			
Diltiazem			
15 to 20 mg May Repeat: 20 to 25 mg after 15 minutes	5 mg/mL	IV	Initial Dose: 20 mg (4 mL) over 2 minutes (min) May repeat after 15 min: 25 mg (5 mL)

Micromedex Assistant 有問題，MA來幫你！

Micromedex 為何需要MA?



資料太多眼昏花

Micromedex 為何需要MA?



**Micromedex
Assistant**



MA相助精準查

怎麼找MA?

Merative **Micromedex**[®]

My Subscription | Gateway | Training Center | Help | Mobile Application Access
| Logout

- Home
- Drug Interactions
- IV Compatibility
- Drug ID
- Drug Comparison
- CareNotes
- NeoFax[®] / Pediatrics
- Tox & Drug Product Lookup
- RED BOOK
- Calculators

Search Drug, Disease, Toxicology, and more

All

Drug

Disease

Toxicology

Keyword search

Micromedex Assistant

Search Micromedex drug information

Type a quick question... →

Learn more



Latest News

- Content Update Highlights
- New/Expanded Drug Indications...
- \$25 gift card for your thoughts

Read Top News



Support & Training

- Training Center
- User Guide
- Micromedex Compendia Resources
- Citing Micromedex

Support Request




Resources

- Black Box Warnings
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS




Download Mobile Apps

怎麼問MA?



點按Learn more即顯示
智能檢索說明



怎麼問MA?

像同事之間一樣問問題

MA現在知道:

藥物資訊


藥物分類、劑量、給藥、藥物安全性、作用、藥物動力學、關於機制

藥物交互作用 單一藥物

IV相容性 Solution, Y site, Admixture, Syringe, TPN / TNA

MA不知道:

NeoFax / Pediatrics, Toxicology, Disease, Lab, Alternative Medicine, Reproductive Risk
第三方內容 (例如Martindale, Index Nominum)



Demo Slides

對話式檢索範例

就像跟你的同事問問題一樣，
對話將提供簡要解答內容、簡要解答連結、深入解答連結

- Dosing and adjustments 劑量與調整
- Adverse effects 不良反應
- Contraindications 禁忌症
- Precautions 注意事項
- Administration 管理
- More 更多

提問範例：

“What’s the adult dose of warfarin for Atrial fibrillation?”

The screenshot shows the Micromedex Assistant interface. At the top, there are search tabs for 'Warfarin So...', 'Atrial fibrillati...', and 'adult', with a 'Clear' button. Below the search bar, a question is displayed: 'What's the adult dose of warfarin for Atrial fibrillation'. The response provides detailed dosing information for warfarin sodium in the context of atrial fibrillation and thromboembolic disorders, including initial and maintenance dosing, and considerations for high-risk patients. A 'Quick Answers Adult Dosing for Warfarin Sodium' button is visible at the bottom of the response area. At the very bottom, there is a 'Was this helpful?' feedback prompt and a text input field labeled 'Type something...'.

對話式檢索介面

智能過濾器

Warfarin ... x Atrial fibr... x adult x Clear

簡要解答內容

Here is the adult dosing for warfarin sodium:

Atrial fibrillation - Thromboembolic disorder

- Initial, 2 to 5 mg orally once a day; adjust dose based on the results of INR; usual maintenance, 2 to 10 mg orally once a day
- Following an ischemic stroke or transient ischemic attack, target an INR of 2.5 (range, 2 to 3). Initiation of therapy within 14 days is reasonable, but initiation may be delayed beyond 14 days in presence of high risk for hemorrhagic conversion (guideline dosing)

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

- Initial, 2 to 5 mg orally once a day; adjust dose based on INR; usual maintenance, 2 to 10 mg orally once a day


簡要解答連結

Quick Answers Adult Dosing for Warfarin Sodium

深入解答連結


In-Depth Answers Adult Dosing for Warfarin Sodium

意見回饋

Was this helpful?  

對話檢索框

Type something...



Micromedex Assistant

Warfarin So... x Atrial fibrillati... x adult x Clear

What's the adult dose of warfarin for Atrial fibrillation

Here is the adult dosing for warfarin sodium:



Atrial fibrillation - Thromboembolic disorder

- Initial, 2 to 5 mg orally once a day; adjust dose based on a target INR of 2.5 (range, 2 to 3); usual maintenance, 2 to 10 mg orally once a day (FDA dosage)
- Duration of therapy: Provide long-term anticoagulation for patients with persistent or paroxysmal non-valvular atrial fibrillation (AF) at high stroke risk (prior ischemic stroke, TIA, systemic embolism, or 2 risk factors) or intermediate stroke risk (1 risk factor), in patients with AF and mitral stenosis, and in patients with prosthetic heart valves (target INR may be increased and concomitant aspirin added depending on valve type, position, and patient factors). Risk factors are older than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus (FDA dosage)
- Following an ischemic stroke or TIA, target an INR of 2.5 (range, 2 to 3). Initiation of therapy within 14 days is reasonable, but initiation may be delayed beyond 14 days in presence of high risk for hemorrhagic conversion (guideline dosage)

Atrial fibrillation - Thromboembolic disorder; Prophylaxis

- Initial, 2 to 5 mg orally once a day; adjust dose based on a target INR of 2.5 (range, 2 to 3); usual maintenance, 2 to 10 mg orally once a day
- Duration of therapy: Provide long-term anticoagulation for patients with persistent or paroxysmal non-valvular atrial fibrillation (AF) at high stroke risk (prior ischemic stroke, TIA, systemic embolism, or 2 risk factors) or intermediate stroke risk (1 risk factor), in patients with AF and mitral stenosis, and in patients with prosthetic heart valves (target INR may be increased and concomitant aspirin added depending on valve type, position, and patient factors). Risk factors are older than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus

Quick Answers Adult Dosing for Warfarin Sodium

Was this helpful?  

Type something...

對話式檢索範例

無論是手滑打錯、語意不明、病名縮寫都沒關係，MA會再次確認，提供你正確答案

提問範例：
adult warfarin AF

Which of the following subjects would you like to see?

Dosing

The screenshot shows the Micromedex Assistant interface. At the top, there are search tabs for 'Warfarin So...', 'Atrial fibrillati...', and 'adult', with a 'Clear' button. A search input field contains 'adult warfarin AF'. Below the search bar, a list of subjects is displayed: 'Adverse Effects', 'Precautions', 'Contraindications', 'Uses', and 'Dosing'. The 'Dosing' option is selected, and the interface displays the following information:

Which of the following subjects would you like to see?

- Adverse Effects
- Precautions
- Contraindications
- Uses
- Dosing

Here is the adult dosing for warfarin sodium:

Atrial fibrillation - Thromboembolic disorder

- Initial, 2 to 5 mg orally once a day; adjust dose based on a target INR of 2.5 (range, 2 to 3); usual maintenance, 2 to 10 mg orally once a day (FDA dosage)
- Duration of therapy: Provide long-term anticoagulation for patients with persistent or paroxysmal non-valvular atrial fibrillation (AF) at high stroke risk (prior ischemic stroke, TIA, systemic embolism, or 2 risk factors) or intermediate stroke risk (1 risk factor), in patients with AF and mitral stenosis, and in patients with prosthetic heart valves (target INR may be increased and concomitant aspirin added depending on valve type, position, and patient factors). Risk factors are older than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus (FDA dosage).
- Following an ischemic stroke or TIA, target an INR of 2.5 (range, 2 to 3). Initiation of therapy within 14 days is reasonable, but initiation may be delayed beyond 14 days in presence of high risk for hemorrhagic conversion (guideline dosage)

Was this helpful?

Type something...

對話式檢索範例

您可延續前面問題繼續發問，智慧過濾器將根據前面提出的問題，提供與前述病患相關背景的解答

提問範例：

Are dose adjustment needed?

Micromedex Assistant

Warfarin So... x Atrial fibrillati... x adult x Clear

In-Depth Answers Adult Dosing for Warfarin Sodium

Are dose adjustment needed

Here are the warfarin sodium dose adjustments:

- Renal impairment: No adjustment necessary; monitor INR more frequently in patients with compromised renal function to maintain INR within the therapeutic range
- Geriatric: Consider using lower initial and maintenance dosage
- Asian patients: Consider using lower initial and maintenance dosage .
- INR: single out of range value, below or above the therapeutic INR by 0.5 or less, continue current warfarin dose and test INR within 1 to 2 weeks
- Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy): May require approximately 25% reduction in daily dosage in the postoperative period .
- Discontinuing therapy: Abrupt discontinuation is suggested rather than gradual tapering of the dose (ACCP guidelines)
- Postpartum: Women who require more than 6 weeks of postpartum anticoagulation may be initiated on warfarin (initial dose, 5 mg daily for 2 days, then adjusted per INR) and bridged with adjusted-dose low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) until INR is in the therapeutic range of 2 to 3 for 2 days, or a direct oral anticoagulant if not breastfeeding. For women with mechanical heart valves, warfarin can be resumed 24 hours after delivery, with overlapping IV UFH (or LMWH) until therapeutic on warfarin .
- Pregnancy, mechanical valve: Warfarin to goal INR plus aspirin 75 mg to 100 mg/day during second and third trimesters; during first trimester, warfarin may be continued in patients who can achieve therapeutic INR with doses of 5 mg/day or less. Frequent monitoring required. Discontinue warfarin and initiate continuous infusion unfractionated heparin prior to planned vaginal delivery (guideline dosing) .

Quick Answers Warfarin Sodium Dose Adjustments

In-Depth Answers Warfarin Sodium Dose Adjustments

Was this helpful?

Type something...

對話式檢索範例

您可延續前面問題繼續發問，智慧過濾器將根據前面提出的問題，提供與前述病患相關背景的解答

提問範例：

What patient monitoring is needed?

The screenshot shows the Micromedex Assistant interface. At the top, there are search filters for 'Warfarin So...', 'Atrial fibrillati...', and 'adult', along with a 'Clear' button. Below the filters, a search bar contains the question 'What patient monitoring is needed?'. The main content area displays the following information:

Here is the warfarin sodium monitoring information:

- INR: daily following the initial dose until the INR stabilized to the therapeutic range; then periodically based on clinical need, generally every 1 to 4 weeks; additional INR testing when other warfarin products are interchanged with Coumadin(R) or when other drugs (including botanicals) are initiated, discontinued, have dosages changed, or taken irregularly; patients with a high risk of bleeding may require more frequent INR monitoring (manufacturer)
- INR: up to every 12 weeks in patients with consistently stable INRs, defined as at least 3 months of consistent results with no need to adjust warfarin dosing; evaluate INR within 1 to 2 weeks if the patient experiences a single out of range value, below or above the therapeutic INR by 0.5 or less (American College of Chest Physicians guidelines)
- INR: Immediately prior to any dental or surgical procedure
- INR (pediatric): More frequently to ensure target INR is achieved and maintained the low-dose prophylactic target INR is 1.7 (range 1.5 to 1.9)
- INR: More frequently in patients with high risk of bleeding, when starting or stopping other drugs, changing dosages of other drugs, and in patients with renal impairment
- INR (when administered with heparin): Sample at least 5 hours after the last IV bolus dose of heparin, 4 hours after stopping continuous IV heparin infusion, 24 hours after the last subcutaneous heparin injection
- Target INR: 2.5 (range, 2 to 3) in adults and pediatric patients in most indications
- Target INR: 3 (range 2.5 to 3.5) mechanical mitral valve, mechanical heart valves in both the aortic and mitral position, those undergoing percutaneous mitral balloon valvotomy with preprocedural transesophageal echocardiogram who demonstrate a left atrial thrombus, caged ball or caged disk valves , caged ball or caged disk valves
- Pregnancy test: Prior to initiation in female patients of reproductive potential
- Signs or symptoms of bleeding: Regularly during therapy, with more frequent monitoring in those with increased risk (high intensity of anticoagulation (INR greater than 4.0), age 65 years or older, history of highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, anemia, malignancy, trauma, renal impairment, VKORC1 and CYP2C9 gene variants, concomitant use of drugs with increased bleeding risk and long duration of therapy)

At the bottom right of the content area, there is a 'Was this helpful?' prompt with thumbs up and thumbs down icons. Below the content area is a text input field labeled 'Type something...'.

對話式檢索範例

如在前述問題下接續詢問前述藥物與特定藥物的交互作用，結果將提供連結引導您到藥物交互作用的頁面

提問範例：

Are there interactions with TAMOXIFEN?

Here are the drug interactions for tamoxifen citrate:

[View Drug Interactions Results](#)

Micromedex Assistant

Tamoxifen C... x Atrial fibrillati... x adult x Clear

Drug Interaction Results ← 修改相互作用

細化方式: Drug Tamoxifen Citrate 嚴重性: All 文件: All

跳轉到: Drug-Drug (111) | 過敏症狀 (0) | 食物 (0) | 乙醇 (0) | 實驗室 (0) | 抽煙 (0) | 懷孕 (1) | 哺乳期 (1)

Drug-Drug 相互作用 (111)

藥物:	嚴重性:	文件:
MESORIDAZINE -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Excellent
WARFARIN [Systemic] -- TAMOXIFEN [Systemic]	Contraindicated	Good
ZIPRASIDONE -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Fair
SAQUINAVIR -- QT INTERVAL PROLONGING DRUGS	Contraindicated	Fair

Are there interactions with TAMOXIFEN?

Here are the drug interactions for tamoxifen citrate:

[View Drug Interactions Results](#)

Was this helpful? 👍 🗨

[Type something...]

對話式檢索範例

除單一藥物的交互作用清單外，亦可直接查詢多個藥物交互作用

提問範例：
interactions among bilberry
Losartan Warfarin ibuprofen?

I've found multiple results for drug.
Which one are you looking for?

- Ibuprofen
- Ibuprofen Lysine

Ibuprofen

Here are the drug interactions for ibuprofen, losartan potassium and warfarin sodium:

[View Drug Interactions Results](#)

Micromedex Assistant

Drug Interaction Results

優化方式: 劑型: All 嚴重性: All 文件: All 類型: All

篩選到: 藥物-藥物 (2) | 複方 (0) | 過敏症狀 (0) | 食物 (13) | 乙醇 (1) | 實驗室 (1) | 抽屜 (1) | 懷孕 (3) | 哺乳期 (3)

藥物:	嚴重性:	文件:	描述:
IBUPROFEN -- WARFARIN SODIUM	Major	Fair	Concurrent use of ANTICOAGULANTS and NSAIDS may result in increased risk of bleeding.
IBUPROFEN -- LOSARTAN POTASSIUM	Moderate	Excellent	Concurrent use of ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS and NSAIDS may result in renal dysfunction and/or increased blood pressure.

複方 (未找到)

Drug-過敏症狀 相互作用 (未找到)

藥物:	嚴重性:	文件:	描述:
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
WARFARIN SODIUM	Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.

interactions among bilberry Losartan Warfarin ibuprofen?

I've found multiple results for drug. Which one are you looking for?

- Ibuprofen
- Ibuprofen Lysine

Ibuprofen

Here are the drug interactions for ibuprofen, losartan potassium and warfarin sodium:

[View Drug Interactions Results](#)

Was this helpful?

Type something...

對話式檢索範例

若您提出新藥或新病患問題繼續發問，MA 將為您重置問題情境並提供相關解答，您無須自行清除前述提問

提問範例：
what drug treat gout?

The screenshot shows the Micromedex Assistant interface. At the top, there are search filters for 'Ibuprofen', 'Losartan Pot...', 'Warfarin So...', 'Gout', and 'adult'. A 'Clear' button is visible. The main search input contains the text 'what drug treat gout?'. Below the input, the response reads: 'Here are the drugs used for adult gout: Effective'. A list of drug categories and specific drug names follows:

- Gout
 - Allopurinol
- Gout - Hyperuricemia
 - Lesinurad/Allopurinol
- Gout, Inadequate response to, intolerant of, or not eligible for allopurinol - Hyperuricemia
 - Febuxostat
- Gout, Refractory to conventional therapy
 - Pegloticase
- Gout, acute
 - Colchicine
 - Indomethacin
 - Naproxen
 - Naproxen Sodium
 - Piroxicam
 - Sulindac
- Gout, acute, Short-term to tide patient over acute episode or exacerbation; Adjunct
 - Betamethasone Sodium Phosphate/Betamethasone Acetate
 - Methylprednisolone
 - Methylprednisolone Acetate
 - Methylprednisolone Sodium Succinate
 - Prednisolone
 - Prednisolone Sodium Phosphate
 - Prednisone
 - Triamcinolone Acetonide
- Gout, acute; Prophylaxis


At the bottom right, there is a 'Was this helpful?' prompt with thumbs up and thumbs down icons. Below the response is a text input field labeled 'Type something...'.

對話式檢索範例

若您提出新藥或新病患問題繼續發問，MA 將為您重置問題情境並提供相關解答，或是追問細節以釐清問題，您無須自行清除前述提問

提問範例：
what are the drugs that treat AF

Here are the drugs used for adult atrial fibrillation:



The screenshot shows the Micromedex Assistant interface. At the top, there are search filters for 'Ibuprofen', 'Losartan Pot...', 'Warfarin So...', 'Atrial fibrillati...', and 'adult'. A 'Clear' button is visible. Below the filters, a search bar contains the query 'what are the drugs that treat AF'. The response area displays the text 'Here are the drugs used for adult atrial fibrillation:' followed by a list of drug classes and specific medications. At the bottom right, there is a 'Was this helpful?' feedback prompt and a 'Type something...' input field.

Micromedex Assistant

Ibuprofen x Losartan Pot... x Warfarin So... x Clear

Atrial fibrillati... x adult x

what are the drugs that treat AF

Here are the drugs used for adult atrial fibrillation:

Effective

- Atrial fibrillation - Thromboembolic disorder
 - Warfarin Sodium
- Atrial fibrillation - Thromboembolic disorder, Prophylaxis
 - Warfarin Sodium
- Atrial fibrillation and flutter
 - Dofetilide
 - Sotalol Hydrochloride
 - Verapamil Hydrochloride
- Atrial fibrillation and flutter - Cardioversion
 - Quinidine Gluconate
 - Quinidine Sulfate
- Atrial fibrillation and flutter - Chemical cardioversion
 - Dofetilide
- Atrial fibrillation and flutter, Chronic therapy to reduce frequency of recurrence
 - Quinidine Gluconate
- Atrial fibrillation and flutter, Chronic therapy to reduce recurrence
 - Quinidine Sulfate
- Atrial fibrillation and flutter, Symptomatic paroxysmal or episodic in patients without structural heart disease
 - Propafenone Hydrochloride
- Atrial fibrillation, In sinus rhythm with history of paroxysmal or persistent atrial fibrillation
 - Dronedaron Hydrochloride
- Atrial fibrillation, Nonvalvular - Cerebrovascular accident; Prophylaxis - Embolism, Systemic; Prophylaxis
 - Apixaban
 - Dabigatran Etexilate Mesylate
 - Bisoprolol

Was this helpful? 👍 🗨

Type something...

Q & A Thank You!

客戶服務中心

服務專線：02-7731-5800

服務傳真：02-8226-5022

客戶服務信箱：services@customer-support.com.tw

專人服務時間：週一～週五 9:00~17:30

系統服務時間：全年無休